Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRD1 | O95696 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6118587 | 0.88 | CYP3A4 (0.51) | CYP3A4HTR6IDH1NSD2BRD4 | |
| SCHEMBL6117937 | 0.87 | CYP3A4 (0.50) | CYP3A4HTR6BRD4UTS2RHTR1A | |
| SCHEMBL2170725 | 0.84 | CYP3A4 (0.50) | CYP3A4HTR6NSD2BRD4MAPT | |
| SCHEMBL6118762 | 0.84 | CYP3A4 (0.50) | CYP3A4HTR6NSD2BRD4UTS2R | |
| SCHEMBL2172090 | 0.80 | POLB (0.53) | CYP3A4KMT2ABRD4MAPTLMNA | |
| SCHEMBL2170411 | 0.80 | CYP3A4 (0.58) | CYP3A4HTR6KMT2ANSD2BRD4 | |
| SCHEMBL2185914 | 0.78 | ALDH1A1 (0.50) | CYP3A4HTR6NSD2BRD4UTS2R | |
| SCHEMBL6117477 | 0.78 | TP53 (0.47) | CYP3A4HTR6KMT2ABRD4MAPT | |
| SCHEMBL2169909 | 0.77 | CYP3A4 (0.54) | CYP3A4HTR6BRD4MAPTHTR1A | |
| SCHEMBL2169531 | 0.77 | HTR6 (0.49) | CYP3A4HTR6KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346847-B1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-15 | — | — | EP | claimed |
| US-8404720-B2 | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-03-26 | — | — | US | claimed |
| US-20120129816-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-05-24 | — | — | US | claimed |
| EP-2346847-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2011-07-27 | — | — | EP | claimed |
| WO-2010032258-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| EP-2346847-B1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-15 | — | — | EP | disclosed |
| US-8404720-B2 | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-03-26 | — | — | US | disclosed |
| US-20120129816-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-05-24 | — | — | US | disclosed |
| EP-2346847-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010032258-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129816-A1 | ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR5A | CYP3A4 119/4885HTR6 1/4885IDH1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.